Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BHV-7000 Efficacy Against Epileptiform Activity in Patients With Epilepsy Implanted With RNS
NCT07125261Phase 1Completed
- Sponsor
- Yale University
- Start
- Oct 2025
- Primary completion
- Mar 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of opakalim in focal epilepsy, sponsored by Yale University. Primary endpoints: Reduction in patient-specific seizure surrogate rate at 28 days, Reduction in seizure onset pattern rate at 28 days and 2 more. Started Oct 2025; status: completed.
02
Drugs
opakalim
03
Conditions
focal epilepsy
Beyond the preview
Go deeper on NCT07125261.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07125261.